Novo Nordisk has officially launched Ozempic in India, marking a significant expansion of its presence in one of the world’s fastest-growing markets for diabetes and obesity treatments.
The launch comes at a time when demand for weight-loss drugs is rising sharply, driven by lifestyle changes, urbanisation, and increasing awareness of metabolic health.
India already has the second-highest number of people with type 2 diabetes globally, after China, alongside steadily climbing obesity rates.
For Novo, the Indian rollout represents both a commercial opportunity and a strategic move to establish early scale before lower-cost competitors enter the market.
Pricing and dosage strategy
Ozempic will be sold in India in a pen format, with three dosage options of 0.25 mg, 0.5 mg, and 1 mg.
Each pen contains four weekly doses, aligning with the drug’s once-a-week injection schedule.
Novo Nordisk has priced the 0.25 mg dose at Rs 8,800 per month, equivalent to about $24.35 per week.
The 0.5 mg version is priced at Rs 10,170 per month, while the 1 mg dose costs Rs 11,175 monthly.
The tiered pricing structure reflects a balance between accessibility and premium positioning in a price-sensitive healthcare market.
Medical use and broader benefits
Ozempic, whose active ingredient is semaglutide, was approved by the US Food and Drug Administration in 2017 for the treatment of type 2 diabetes.
Since then, it has become a global bestseller.
While its primary indication is glycaemic control, the drug is widely used off-label for weight loss due to its appetite-suppressing effects.
Beyond blood sugar regulation, the medication has also been shown to reduce the risk of cardiovascular events and kidney-related complications in people with diabetes.
Clinical experience indicates that patients with diabetes can experience weight loss of up to eight kilograms, highlighting benefits that extend beyond glucose management.
India as a key growth market
India’s large and growing patient base makes it a critical battleground for global drugmakers targeting metabolic diseases.
Rising disposable incomes, changing diets, and sedentary lifestyles have contributed to an increase in both diabetes and obesity prevalence.
This has created strong demand for newer, more effective treatments, particularly injectable therapies with proven outcomes.
Experts estimate that the global weight-loss drug segment could reach $150 billion in annual sales by the end of the decade, underscoring why companies like Novo are moving quickly to secure market share in high-growth regions such as India.
Competitive timing and patent horizon
According to Reuters, Novo Nordisk’s India launch follows earlier indications that the company was aiming to introduce Ozempic this month to establish a foothold ahead of domestic generic manufacturers.
That timing is significant, as semaglutide is set to go off patent in March 2026.
Once exclusivity ends, Indian drugmakers are expected to roll out cheaper versions, intensifying competition and putting pressure on pricing.
By entering the market now, Novo gains brand recognition and physician familiarity before generics arrive, potentially helping it retain a segment of patients even as alternatives become available.
The post Novo Nordisk brings Ozempic to India as weight-loss demand accelerates appeared first on Invezz
